Full-Time

Senior Medical Director

Clinical Development

Updated on 9/3/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$293k - $379.5k/yr

+ Annual bonus + Long-term incentive award/equity

Boston, MA, USA

Hybrid

At least two days on-site per week, currently Tuesday and Wednesday; additional on-site days may be required.

MBA, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Biostatistics

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • An MD or DO degree is required.
  • A minimum of 10 years of combined clinical and pharmaceutical or biotechnology industry experience is required.
  • A minimum of 5 years in a clinical development role with increasing levels of responsibility is preferred.
  • Deep scientific expertise in autoimmune disease is required, with rheumatology preferred.
  • Demonstrated experience serving as a physician lead on Phase I through Phase III clinical programs, including hands-on protocol development, medical monitoring, and regulatory submission experience.
  • Deep clinical and scientific expertise in immunology and inflammation, including disease mechanisms, clinical trial landscapes, standard-of-care evolution, regulatory developments, and emerging therapeutic approaches.
  • Proven ability to identify, characterize, and mitigate clinical, operational, and regulatory risks across multisite, multinational clinical programs.
  • Demonstrated ability to serve as the senior medical authority on cross-functional program teams, set scientific direction, resolve complex medical questions, and build alignment across diverse functional stakeholders.
  • A strong track record of leading clinical programs through critical milestones, including first-in-human studies, proof-of-concept readouts, pivotal trial initiation, and regulatory submissions.
  • Ability to deliver data-driven recommendations to senior leadership and adapt communication to drive informed decision-making at organizational and portfolio levels.
  • Ability to build trust and credibility with clinical investigators, key opinion leaders, and regulatory agencies.
  • Exceptional scientific and medical communication skills, including presenting complex clinical data, safety findings, and development strategies to regulators, investigators, executives, and patient communities.
  • Skill in authoring and reviewing clinical documents, including protocols, investigator brochures, clinical study reports, regulatory briefing documents, and scientific manuscripts.
Responsibilities
  • Serve as the physician medical lead for assigned clinical development programs, owning the clinical development strategy, integrated development plan, and medical decision-making for pipeline assets across Phase I through Phase III development.
  • Lead the design, authorship, and review of clinical trial protocols, investigator brochures, informed consent documents, and clinical sections of regulatory submissions, including Investigational New Drug, New Drug Application, biologics license application, and global filings.
  • Provide comprehensive medical oversight of ongoing clinical trials, including safety monitoring, medical monitoring, serious adverse event assessment, protocol deviation review, and benefit-risk evaluation, in partnership with Clinical Operations, Pharmacovigilance, and Biostatistics.
  • Lead and represent the organization in regulatory agency interactions, including Food and Drug Administration and European Medicines Agency meetings, briefing document development, and responses to health authority questions.
  • Support pharmacovigilance activities during trial conduct.
  • Drive cross-functional clinical program teams as the senior medical lead, providing strategic scientific direction to Clinical Operations, Regulatory Affairs, Translational Medicine, Biostatistics, and Medical Affairs, and ensuring integrated program execution with clear accountability and pace.
  • Build and maintain relationships with key opinion leaders, principal investigators, and academic medical centers to strengthen the clinical network, gather external scientific insights, and support the medical positioning of pipeline assets.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • Board certification or clinical training in rheumatology, nephrology, immunology, or a related specialty.
  • An additional advanced degree such as a PhD, Master of Public Health, or Master of Business Administration.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...